PDUFA Fees Push Higher In FY 2024, While Biosimilar Fees Race Downward

 
• By Derrick Gingery

Fiscal year 2024 prescription drug user fees skyrocket in part because of a low application volume in FY 2022, while biosimilar user fees continue to drop due to the program’s healthy operating reserve.

money bag handed over
New drug sponsors will hand over a lot more money with their FDA applications in FY 2024. • Source: Shutterstock

More from User Fees

More from Pathways & Standards